SB 299 amends Tennessee's medical cannabis commission membership requirements to include a patient caregiver (or former caregiver of a deceased patient) and a subject matter expert in cannabis cultivation, processing, distribution, or medical prescription. The bill also updates the commission's reporting duties to explicitly allow it to provide policy recommendations to the legislature alongside its findings. These changes, effective April 15, 2025, directly affect how the commission is structured and the scope of its advice to lawmakers on medical cannabis policy.
HB 1349 requires county medical examiners to test decedents involved in mass shootings resulting in four or more deaths for psychotropic drugs (medications treating mental health conditions or affecting mood/behavior). It mandates that examiners share anonymized drug data - without identifying information - to the University of Tennessee Health Science Center and the Department of Health. The Health Science Center must study drug interactions and submit quarterly reports to legislative committees on this data. This bill directly affects medical examiners, health agencies, and the research conducted on drug-related incidents in Tennessee.
SB 849 requires Tennessee medical and osteopathic boards to create an optional continuing education course on maternal mental health for healthcare professionals. It directly affects physicians specializing in obstetrics/gynecology, pediatrics, and psychiatry, as well as certain psychologists. The course must cover screening practices, types of maternal mental health disorders, evidence-based treatments, and when to consult a psychiatrist. Boards must update the curriculum periodically to reflect new research and accept course completion as credit toward required continuing education.
SB 1146 requires county medical examiners to test decedents involved in mass shootings (resulting in four or more deaths) for all drugs, including psychotropic medications used for mental health conditions. It mandates anonymized data sharing with the University of Tennessee Health Science Center and the Department of Health, prohibiting disclosure of identifying information. The health science center must study drug interactions and submit quarterly reports to legislative health committees. The law, effective July 1, 2025, applies to medical examiners, health agencies, and the University of Tennessee, while requiring compliance with privacy laws.
SB 955, now known as the "Medical Ethics Defense Act," protects Tennessee healthcare providers from being forced to participate in or pay for medical procedures that conflict with their conscience. It defines "conscience" as sincerely held ethical, moral, or religious beliefs and prohibits discriminatory actions - like termination or penalties - against providers who refuse specific procedures based on those beliefs. The law also safeguards providers who report violations of this act, preventing retaliation for whistleblowing. This applies to healthcare professionals, institutions, and payers but excludes procedures governed by federal law (such as emergency care under EMTALA).
SB 449, the "Fertility Treatment and Contraceptive Protection Act," establishes legal rights for individuals in Tennessee to access fertility treatments and contraception without state prohibition. It defines "fertility treatment" broadly to include procedures like in vitro fertilization, genetic testing of embryos, and medication for fertility, while defining "contraception" to cover methods such as birth control pills, emergency contraceptives, and sterilization. The law explicitly states that Tennessee law does not prohibit these activities, overriding conflicting state laws. This act takes effect on July 1, 2025, directly affecting all residents seeking these health services within the state.
HB 830 amends Tennessee law to change membership requirements for the Medical Cannabis Commission. It adds two new membership categories: (1) a patient caregiver (with documentation of their patient relationship), and (2) a subject matter expert knowledgeable in cannabis cultivation, processing, shipping, distribution, or medical prescription. The bill also updates the commission’s reporting duty to explicitly allow it to include policy recommendations in its reports to the Tennessee General Assembly. This enacted law (effective April 29, 2025) directly affects who serves on the commission and the scope of its advisory role.
HB 533, now Public Chapter 247, establishes the "Fertility Treatment and Contraceptive Protection Act" in Tennessee. It defines fertility treatment (including IVF, egg/sperm preservation, and genetic testing) and contraception (covering all pregnancy prevention methods, including over-the-counter options) and explicitly states that Tennessee law does not prohibit these activities. The bill directly affects all Tennesseans seeking reproductive healthcare by guaranteeing the right to access fertility services and contraception without state interference. Key provisions clarify that the state cannot ban or restrict these services, overriding conflicting existing laws. This law took effect immediately upon becoming public on April 29, 2025.
HB 1044, now Public Chapter 266, enacts Tennessee's "Medical Ethics Defense Act" to protect healthcare providers' rights to refuse care based on conscience. It prohibits discrimination against providers who decline to participate in specific procedures (like certain reproductive or end-of-life care) that conflict with their ethical, moral, or religious beliefs, as defined in the law. The bill also shields providers from retaliation for reporting violations of these protections or disclosing concerns about patient safety. It explicitly excludes federal laws like EMTALA and religious institutions' employment decisions from its scope.
HB 1198 requires Tennessee health insurers and TennCare to allow patients to try biosimilar drugs (cost-effective copies of brand-name medications) before covering the original branded drug. It amends state law to permit health carriers to mandate a biosimilar trial for equivalent branded prescriptions, removing prior requirements for generic drug trials. The bill also directs TennCare’s pharmacy committee to consider biosimilar drugs when recommending medications for the state’s preferred drug list. These changes aim to reduce prescription drug costs by increasing biosimilar adoption, as stated in the bill’s legislative findings.
